FGEN (FibroGen, Inc.) קצב צמיחת רווח למניה בשנה הנוכחית
A critical capital reduction and the threat of delisting following failures with pamrevlumab have placed serious pressure on FibroGen, Inc. (FGEN). FibroGen, Inc. (FGEN) generates revenue from the commercialization of fibrosis and anemia treatments, including partner payments. The brand's scientific authority is confirmed by the success of roxadustat. Looking at the annual earnings per share change on GURU.Markets, we see that the value of this metric is 61.80.
פילוחי מדדים פיננסיים ומדדי שוק עבור FibroGen, Inc. (FGEN)
This metric measures the year-over-year dynamics of net earnings per share, determining the growth or decline rates of the business's actual earnings over a twelve-month period. By analyzing the annual EPS growth indicator, an investor filters out market noise. For FibroGen, Inc. (FGEN), this reflects the commercialization efficiency of the drug Evaren within the nephrology segment. A positive trend confirms the successful substitution of injections with the oral form.
